Affymax, Inc. company was founded in 2001 and is based in Palo Alto, California. Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. The company’s lead product candidate, Hematide, is designed to treat anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. It is conducting Phase III clinical trials for the treatment of anemia associated with chronic renal failure, on dialysis, and pre-dialysis. Affymax has a license, manufacturing, and supply agreement with Nektar Therapeutics AL, Corporation to manufacture, develop, and commercialize Hematide.

Medical Nutrition USA, Inc. engages in the development and distribution of nutritional and health products in the United States. Its products primarily include the Pro-Stat line of enzyme-hydrolyzed liquid protein for the treatment of unintended weight loss, protein energy malnutrition, and pressure ulcers; UTI-Stat, a urinary tract cleansing complex used to reduce the incidence of urinary tract infection and promote urinary tract health; and Fiber-Stat, a liquid soluble fiber with FOS used to maintain bowel regularity and probiotic intestinal health. Medical Nutrition company's customers include long-term care facilities, hospitals, dialysis clinics, physicians, dispensing medical clinics, nursing homes, and network marketing companies. Medical Nutrition USA sells its branded products directly to distributors, who resell the products to end users, as well as sells through health food stores under private label or licensing agreements. Medical Nutrition USA, Inc. is based in Englewood, New Jersey.

Alexza Pharmaceuticals, Inc. was founded in 2000 and is based in Mountain View, California. Alexza Pharmaceuticals, Inc., a specialty pharmaceutical development stage company, focuses on the research, development, and commercialization of products for the acute treatment of central nervous system conditions. Its technology, Staccato system, vaporizes an excipient-free drug to form a condensation aerosol that allows for systemic drug delivery. The company has six product candidates in clinical development, including AZ-004 (Staccato loxapine) that completed Phase 3 clinical trial for the acute treatment of agitation in patients with schizophrenia or bipolar disorder; AZ-104 (Staccato loxapine), which completed Phase 2a clinical trial to treat patients suffering from acute migraine headaches; and AZ-001 (Staccato prochlorperazine) that completed Phase 2b clinical trials to treat patients suffering from acute migraine headaches.Alexza products in clinical development also include AZ-007 (Staccato zaleplon), which completed Phase 1 clinical trial for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep; AZ-003 that completed Phase 1 clinical trial (Staccato fentanyl) for the treatment of patients with acute pain, including patients with breakthrough cancer pain and postoperative patients with acute pain episodes; and AZ-002 (Staccato alprazolam), which completed Phase 2a proof-of-concept clinical trial for the treatment of panic attacks. The company has a development agreement with Autoliv ASP, Inc. to develop heat packages to incorporate into the company's single dose drug delivery devices. It was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005.

U.S. Genomics, Inc. company has developed the GeneEngine, a DNA sequencer that mimics natural cell division, rapidly reading and copying DNA. It is developing the technology to quickly detect and identify infectious pathogens and biomarkers for biodefense and diagnostic use. Its products can detect and quantify molecules of DNA, RNA, and proteins without amplification. Backed by private equity investors and biomedical firms including Becton Dickinson, U.S. Genomics has netted contracts with the Department of Homeland Security. Northrup Gruman is the company's bio-security development partner.

Purely Proteins doesn't mix your ordinary protein shake. Through its proprietary technology, the company purifies human proteins to accelerate biotherapeutic drug discovery and drug screening. Purely Proteins also operates a subscription-based online database of gene and protein information called TargetBASE, which gives chemists and biologists a summary of known and potential protein targets that may help in the discovery of therapies for diabetes, cancer, and Alzheimer's disease. The company conducts its research in conjunction with several business partners, including Abcam Ltd, Asahi Kasei, Cytomyx Limited, and Inhibox Ltd. CEO David Parry-Smith co-founded Purely Proteins in 2002.

Ceragenix Pharmaceuticals was founded in 2002 is based in Denver, Colorado. Ceragenix Pharmaceuticals, Inc. operates as a medical device company focusing on infectious diseases and dermatology in the United States. The company has two base technology platforms, which include Ceragenins for the treatment of infectious disease; and Barrier Repair for the treatment of dermatological disorders, including atopic dermatitis, neonatal skin disorders, and others. Its Ceragenin compounds are active against a range of gram positive and negative bacteria. The company uses its Ceragenin technology to formulate Cerashield antimicrobial coatings for medical devices. Its Barrier Repair technology is the platform for the development of two prescription topical creams, including EpiCeram, a prescription product for the treatment of dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatoses, including eczema, irritant contact dermatitis, and radiation dermatitis; and NeoCeram, a pediatric barrier repair cream intended to create a skin barrier in premature infants and neonates.

Ash Stevens, Inc. was founded in 1962 to provide chemical research for the government and later branched out into the private sector. Ash Stevens, Inc. company, a contract pharmaceutical manufacturer develops and manufactures active pharmaceutical ingredients (APIs) for other pharmaceutical companies. It also supports clinical drug trials and helps others navigate the FDA's regulatory maze. Its customers include the federal government and commercial pharmaceutical firms. The company's portfolio includes about a dozen FDA-approved drug components.

3SBio Inc. was founded in 1993 and is based in Shenyang, the Peoples Republic of China. 3SBio Inc. is an integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. The Company’s recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO, and its legacy products are Intefen and Inleusin. EPIAO is an injectable recombinant human erythropoietin (EPO) that is used to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions. 3SBio Inc. had launched TPIAO, its internally developed protein-based therapeutic product. In addition to EPIAO and TPIAO, the Company markets two other protein-based therapeutics.

Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in Union City, California. Questcor Pharmaceuticals, Inc., a specialty pharmaceutical company, provides prescription drugs for central nervous system disorders. The company markets H.P. Acthar Gel (repository corticotropin injection), an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis, and the treatment of nephrotic syndrome. H.P. Acthar Gel is also used in treating patients with infantile spasms, a rare form of refractory childhood epilepsy; and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The company also markets Doral (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.

Genta plays rough with cancer. The firm develops drugs, including DNA/RNA medicines and more traditional small molecule drugs, for cancer and other diseases. Lead candidate Genasense blocks production of a protein that can cause resistance to cancer treatments. The company is hoping for marketing approval of Genasense to be used in conjunction with chemotherapy by patients with lymphocytic leukemia and malignant melanoma. Genasense is also in clinical trials for treatment of other diseases, such as prostate and colon cancer. Its small molecule program yielded Ganite, an FDA-approved treatment for hypercalcemia (a potentially fatal side effect of cancer); but the company does not actively market the drug.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.